This research paper takes a look at the risk of breast cancer from doxorubicin exposure in female survivors of Hodgkin lymphoma who are between the ages of 15-50 years of age and five years post treatment. The period of treatment was between 1975 and 2008. The study was first presented in 2021 at the ASCO Annual Meeting.
Of note is that the authors found an increased risk of breast cancer in this cohort independent of whether or not radiation was also a part of the treatment protocol. Their conclusions include this very important point- one that we will continue to advocate for with fervor.